Report Overview

Proton-pump inhibitors (PPIs) are a group of medications whose main action is a pronounced and long-lasting reduction of stomach acid production.

Proton pump inhibitors (PPIs) reduce the production of acid by blocking the enzyme in the wall of the stomach that produces acid. Acid is necessary for the formation of most ulcers in the esophagus, stomach, and duodenum, and the reduction of acid with PPIs prevents ulcers and allows any ulcers that exist in the esophagus, stomach, and duodenum to heal.

PPIs are among the most widely sold medications in the world. The class of proton-pump inhibitor medications is on the World Health Organization's List of Essential Medicines.

Medically used proton pump inhibitors: Omeprazole, Lansoprazole, Dexlansoprazole, Esomeprazole, Pantoprazole, Rabeprazole.

The global Proton Pump Inhibitors revenue was US$ 12190 million in 2022 and is forecast to a readjusted size of US$ 9680.8 million by 2029 with a CAGR of -3.2% during the forecast period (2023-2029).

In India, the Proton Pump Inhibitors revenue is expected to grow from US$ million in 2022 to US$ million by 2029, at a CAGR of % during the forecast period (2023-2029).

Global Proton Pump Inhibitors key players include AstraZeneca, Takeda, etc. Global top two manufacturers hold a share over 15%.

North America is the largest market, with a share about 30%, followed by Asia-Pacific, and Europe, having a share about 50 percent.

In terms of product, Esomeprazole is the largest segment, with a share about 30%. And in terms of application, the largest application is Hospital Pharmacy, followed by Retail Pharmacy, etc.

This report focuses on global and India Proton Pump Inhibitors market, also covers the segmentation data of other regions in regional level and county level.

India is now the world’s most populous country. According to IMF (its July update to its World Economic Outlook), India’s GDP growth is projected at 6.1% in 2023, powered by domestic investment. First and foremost, the key factor in India's rapid economic growth is the huge supply and demand from a large population base. Demand and supply sides working in both directions to support India's economic stability.

India is a market full of opportunities, and the demand for Proton Pump Inhibitors will continue to grow rapidly in the future.

Global Proton Pump Inhibitors Scope and Market Size

Proton Pump Inhibitors market is segmented in regional and country, by players, by type and by distribution channel. Companies, stakeholders, and other participants in the global Proton Pump Inhibitors market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on revenue and forecast by type and by distribution channel for the period 2018-2029.

For India market, this report focuses on the Proton Pump Inhibitors market size by players, by Type and by Distribution Channel, for the period 2018-2029. The key players include the global and local players, which play important roles in India.

By Company

Takeda

Pfizer

AstraZeneca

Bayer

Sun Pharma

Teva

Eisai Co.

Mylan

AOSAIKANG Pharma

Luoxin Pharma

LIVZON

Eastchina Pharma

Segment by Type

Dexlansoprazole

Esomeprazole

Lansoprazole

Omeprazole

Pantoprazole

Rabeprazole

Segment by Distribution Channel

Hospital Pharmacy

Retail Pharmacy

Others

By Region

Americas

United States

Canada

Mexico

Brazil

China

APAC (excluding China)

Japan

South Korea

China Taiwan

ASEAN

India

EMEA

Europe

Middle East

Africa

Chapter Introduction

Chapter 1: Introduces Proton Pump Inhibitors definition, global sales (volume and revenue), India market size, India percentage in global market. This section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.

Chapter 2: Provides the analysis of various market segments by type, covering the volume, price, revenue, and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 3: Provides the analysis of various market segments by distribution channel, covering the revenue, price, volume, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 4: Detailed analysis of Proton Pump Inhibitors companies’ competitive landscape, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.

Chapter 5: Revenue and volume of Proton Pump Inhibitors in global and regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and capacity of each country in the world.

Chapter 6: Americas by type, by distribution channel and by country, sales, and revenue for each segment.

Chapter 7: EMEA by type, by distribution channel and by region, sales, and revenue for each segment.

Chapter 8: China by type, by distribution channel, sales, and revenue for each segment.

Chapter 9: APAC (excluding China) by type, by distribution channel and by region, sales, and revenue for each segment.

Chapter 10: Provides profiles of key companies, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Proton Pump Inhibitors sales, revenue, gross margin, and recent development, etc.

Chapter 11: Analysis of industrial chain, sales channel, key raw materials, distributors, and customers.

Chapter 12: Research findings and conclusion

OUR INDIA OFFICE

India Office

315 Work Avenue, Raheja Woods,
Kalyani Nagar, Pune,
Maharashtra 411006, India

Report Overview